|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
AR004752A1
(es)
*
|
1995-11-28 |
1999-03-10 |
Schering Corp |
2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
|
|
US5824683A
(en)
*
|
1995-11-28 |
1998-10-20 |
Schering Corporation |
2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
|
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
|
US6403799B1
(en)
*
|
1999-10-21 |
2002-06-11 |
Agouron Pharmaceuticals, Inc. |
Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
|
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
EP1790652A1
(en)
*
|
2001-08-28 |
2007-05-30 |
Schering Corporation |
Polycyclic guanine phosphodiesterase V inhibitors
|
|
CN1781920A
(zh)
*
|
2001-08-28 |
2006-06-07 |
先灵公司 |
多环鸟嘌呤磷酸二酯酶v抑制剂
|
|
CA2459161A1
(en)
*
|
2001-08-31 |
2003-03-13 |
The Rockefeller University |
Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
|
|
MXPA04004370A
(es)
*
|
2001-11-09 |
2004-08-11 |
Schering Corp |
Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
|
|
EP1719772A1
(en)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
|
|
MXPA06001195A
(es)
*
|
2003-07-31 |
2006-04-11 |
Schering Corp |
Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil.
|
|
KR20060101762A
(ko)
*
|
2003-11-21 |
2006-09-26 |
쉐링 코포레이션 |
포스포디에스테라제 v 억제제 제형
|
|
SE0401653D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
New compounds
|
|
US20070004745A1
(en)
*
|
2005-03-25 |
2007-01-04 |
Schering-Plough Corporation |
Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
|
|
AU2006255028B2
(en)
|
2005-06-06 |
2012-04-19 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
WO2007025103A2
(en)
*
|
2005-08-23 |
2007-03-01 |
Intra-Cellular Therapies, Inc. |
Organic compounds for treating reduced dopamine receptor signalling activity
|
|
BRPI0620464A2
(pt)
|
2005-12-23 |
2011-11-16 |
Astrazeneca Ab |
composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença
|
|
JP2009521428A
(ja)
|
2005-12-23 |
2009-06-04 |
アストラゼネカ・アクチエボラーグ |
胃腸疾患治療用のイミダゾール誘導体
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
EP2023729B1
(en)
*
|
2006-06-06 |
2016-05-04 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
US9198924B2
(en)
*
|
2006-11-13 |
2015-12-01 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
WO2008070095A1
(en)
|
2006-12-05 |
2008-06-12 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
|
US7901872B2
(en)
|
2007-05-21 |
2011-03-08 |
Macronix International Co., Ltd. |
Exposure process and photomask set used therein
|
|
AU2008269177A1
(en)
*
|
2007-06-21 |
2008-12-31 |
Schering Corporation |
Polycyclic Guanine Derivatives and use thereof
|
|
JP5068857B2
(ja)
|
2007-12-06 |
2012-11-07 |
武田薬品工業株式会社 |
有機化合物
|
|
KR20100094551A
(ko)
*
|
2007-12-06 |
2010-08-26 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
|
WO2009144548A1
(en)
*
|
2008-05-28 |
2009-12-03 |
Glenmark Pharmaceuticals S.A. |
Imidazo [2,1-b] purine derivatives as trpa1 modulators
|
|
PE20110223A1
(es)
|
2008-06-10 |
2011-05-07 |
Abbvie Inc |
DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA
|
|
JP5813511B2
(ja)
|
2008-12-06 |
2015-11-17 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
|
JP5778582B2
(ja)
|
2008-12-06 |
2015-09-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
|
EP2358723B1
(en)
|
2008-12-06 |
2015-05-13 |
Intra-Cellular Therapies, Inc. |
4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors
|
|
US8927556B2
(en)
|
2008-12-06 |
2015-01-06 |
Intra-Cellular Therapies, Inc. |
1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds
|
|
AU2009322905A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
JP5784501B2
(ja)
|
2008-12-06 |
2015-09-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
|
JP2012518685A
(ja)
|
2009-02-25 |
2012-08-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
眼障害のためのpde1阻害剤
|
|
WO2010132127A1
(en)
|
2009-05-13 |
2010-11-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
SG178279A1
(en)
|
2009-08-05 |
2012-03-29 |
Intra Cellular Therapies Inc |
Novel regulatory proteins and inhibitors
|
|
UY33071A
(es)
|
2009-12-01 |
2011-05-31 |
Abbott Lab |
Nuevos compuestos tricíclicos
|
|
US8785639B2
(en)
|
2009-12-01 |
2014-07-22 |
Abbvie Inc. |
Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
|
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
|
EP2590657A4
(en)
|
2010-05-31 |
2014-02-12 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
|
WO2011153136A1
(en)
|
2010-05-31 |
2011-12-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
EP2576551A4
(en)
|
2010-05-31 |
2014-04-16 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
|
WO2012171016A1
(en)
|
2011-06-10 |
2012-12-13 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
JP6549040B2
(ja)
|
2013-02-17 |
2019-07-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規使用
|
|
US9545406B2
(en)
|
2013-03-15 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Method of treating a CNS injury with a PDE1 inhibitor
|
|
JP6437519B2
(ja)
|
2013-03-15 |
2018-12-12 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
|
JP6696904B2
(ja)
|
2014-01-08 |
2020-05-20 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
製剤および医薬組成物
|
|
US9884872B2
(en)
|
2014-06-20 |
2018-02-06 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
|
WO2016022893A1
(en)
|
2014-08-07 |
2016-02-11 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
KR102332957B1
(ko)
|
2014-09-17 |
2021-11-29 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
화합물 및 방법
|
|
JP6608934B2
(ja)
|
2014-12-06 |
2019-11-20 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
|
BR112017012005B1
(pt)
|
2014-12-06 |
2023-04-04 |
Intra-Cellular Therapies, Inc |
Compostos orgânicos inibidores de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
|
|
SG10201913989QA
(en)
|
2015-10-16 |
2020-03-30 |
Abbvie Inc |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11773106B2
(en)
|
2015-10-16 |
2023-10-03 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
WO2017172795A1
(en)
|
2016-03-28 |
2017-10-05 |
Intra-Cellular Therapies, Inc. |
Novel compositions and methods
|
|
WO2018049417A1
(en)
|
2016-09-12 |
2018-03-15 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
|
EP3562828B1
(en)
|
2016-12-28 |
2026-03-18 |
Dart Neuroscience LLC |
Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
|
|
WO2019104285A1
(en)
|
2017-11-27 |
2019-05-31 |
Dart Neuroscience, Llc |
Substituted furanopyrimidine compounds as pde1 inhibitors
|
|
US11839614B2
(en)
|
2018-01-31 |
2023-12-12 |
Intra-Cellular Therapies, Inc. |
Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
|
|
WO2021046179A1
(en)
|
2019-09-03 |
2021-03-11 |
Intra-Cellular Therapies, Inc. |
Novel compounds
|
|
US12364695B2
(en)
|
2020-06-02 |
2025-07-22 |
Intra-Cellular Therapies, Inc. |
Methods of treating inflammatory disease
|